PP
ALXN

Paloma Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Paloma Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,200
Closed -$1.13M – 2472
2020
Q4 		$1.13M Buy
+7,200
New +$925K 0.03% 537
2020
Q2 		– Sell
-8,010
Closed -$719K – 2314
2020
Q1 		$719K Sell
8,010
-17,937
-69% -$1.76M 0.04% 385
2019
Q4 		$2.81M Buy
25,947
+22,850
+738% +$2.44M 0.04% 455
2019
Q3 		$304K Buy
+3,097
New +$349K 0.01% 1518
2019
Q2 		– Sell
-28,382
Closed -$3.84M – 2326
2019
Q1 		$3.84M Buy
28,382
+14,712
+108% +$1.83M 0.09% 241
2018
Q4 		$1.33M Buy
+13,670
New +$1.62M 0.04% 366
2018
Q3 		– Sell
-1,714
Closed -$215K – 2074
2018
Q2 		$213K Sell
1,714
-16,116
-90% -$1.88M ﹤0.01% 1443
2018
Q1 		$1.99M Buy
17,830
+13,103
+277% +$1.57M 0.03% 577
2017
Q4 		$565K Sell
4,727
-16,482
-78% -$2.01M 0.01% 1298
2017
Q3 		$2.98M Buy
+21,209
New +$2.88M 0.04% 501
2017
Q2 		– Sell
-18,264
Closed -$2.21M – 2523
2017
Q1 		$2.21M Buy
+18,264
New +$2.35M 0.03% 723
2016
Q4 		– Sell
-17,430
Closed -$2.14M – 2222
2016
Q3 		$2.14M Buy
17,430
+3,761
+28% +$484K 0.03% 508
2016
Q2 		$1.6M Buy
13,669
+12,098
+770% +$1.72M 0.02% 857
2016
Q1 		$219K Sell
1,571
-7,840
-83% -$1.15M ﹤0.01% 1653
2015
Q4 		$1.79M Buy
+9,411
New +$1.64M 0.05% 407
2015
Q3 		– Sell
-13,781
Closed -$2.49M – 2045
2015
Q2 		$2.49M Buy
13,781
+10,181
+283% +$1.76M 0.05% 368
2015
Q1 		$624K Buy
3,600
+1,125
+45% +$204K 0.02% 689
2014
Q4 		$458K Sell
2,475
-41,479
-94% -$7.69M 0.02% 707
2014
Q3 		$7.29M Buy
43,954
+10,851
+33% +$1.78M 0.33% 67
2014
Q2 		$5.17M Buy
+33,103
New +$5.23M 0.21% 112

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's ALXN Position: Q1 2021 in Review

Paloma Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 7,200 shares — an estimated $1.13M sold.

Paloma Partners first reported a position in ALXN in Q2 2014 and held it in 20 quarters. The position peaked at $7.29M in Q3 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Paloma Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Paloma Partners sold 7,200 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.13M.
  • Paloma Partners first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 20 quarters.
  • Paloma Partners's Alexion Pharmaceuticals position peaked at $7.29M in Q3 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.